FDA Needs To Develop A "Human Capital Plan" - GAO Report
This article was originally published in The Gray Sheet
Executive Summary
FDA should develop a strategic human capital plan and update its workforce plan, according to the Government Accountability Office. Recent FDA workforce management changes are insufficient, according to GAO
You may also be interested in...
Hamburg Outlines Planned Reforms Of FDA Criminal Investigations Office
FDA Commissioner Margaret Hamburg outlined reforms planned for the agency's Office of Criminal Investigations, including new criteria for selecting misdemeanor prosecution cases against responsible corporate officials
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.